AmgenAMGN
Market Cap: $172B
About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Employees: 26,700
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
59% more funds holding in top 10
Funds holding in top 10: 54 [Q1] → 86 (+32) [Q2]
34% more first-time investments, than exits
New positions opened: 206 | Existing positions closed: 154
19% more call options, than puts
Call options by funds: $2.6B | Put options by funds: $2.18B
9% more capital invested
Capital invested by funds: $119B [Q1] → $129B (+$10.1B) [Q2]
2% more funds holding
Funds holding: 2,649 [Q1] → 2,701 (+52) [Q2]
7% more repeat investments, than reductions
Existing positions increased: 1,110 | Existing positions reduced: 1,038
1.5% less ownership
Funds ownership: 78.22% [Q1] → 76.72% (-1.5%) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
TD Cowen Yaron Weber 100% 1-year accuracy 2 / 2 met price target | 19%upside $381 | Buy Maintained | 7 Aug 2024 |
Oppenheimer Jay Olson 39% 1-year accuracy 19 / 49 met price target | 19%upside $380 | Outperform Maintained | 7 Aug 2024 |
Deutsche Bank James Shin 100% 1-year accuracy 5 / 5 met price target | 5%downside $305 | Hold Reiterated | 7 Aug 2024 |
B of A Securities Geoff Meacham 59% 1-year accuracy 10 / 17 met price target | 3%upside $330 | Neutral Maintained | 7 Aug 2024 |
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target | 13%upside $362 | Outperform Maintained | 7 Aug 2024 |
Financial journalist opinion
Based on 25 articles about AMGN published over the past 30 days